<DOC>
	<DOCNO>NCT01878474</DOCNO>
	<brief_summary>The purpose study assess safety tolerability single dose TA-8995 healthy Caucasian Japanese volunteer .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics Pharmacodynamics TA-8995 With Single , Escalating Doses Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Caucasian men age 1855 year ≥65 year Women nonchildbearing potential Japanese men age 1855 year Subjects deem healthy basis medical history , physical examination , Electrocardiogram ( ECG ) , vital sign safety test blood urine Subjects able give fully inform write consent HDLC level ≥2.59 mmol/L Abnormal Holter ECG Family history long QT syndrome , hypokalaemia Torsade de Pointes Vital sign 12lead ECG value outside acceptable range Positive test hepatitis B C , HIV 1 2 Positive urine pregnancy test ( woman ) Severe adverse reaction allergy drug Drug alcohol abuse Smoking within 6 month dose TA8995 ( Caucasian subject ) , smoke 10 cigarette daily ( Japanese subject ) Overthecounter prescribe medication 7 day 5 halflives ( whichever longer ) dose TA8995 Consuming food drink contain grapefruit cranberry within 7 day dose Participation clinical trial , loss 450 mL blood within previous 3 month Clinically relevant abnormal finding screen assessment Clinically relevant abnormal medical history concurrent medical condition Possibility volunteer would cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>MT-8995</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Cholesteryl ester transfer protein</keyword>
</DOC>